The Latin America, Middle East and Africa Computational Pathology Market is expected to witness market growth of 8.9% CAGR during the forecast period (2025-2032).
The Brazil market dominated the LAMEA Computational Pathology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $38.9 million by 2032. The Argentina market is showcasing a CAGR of 9.7% during 2025-2032. Additionally, the UAE market would register a CAGR of 7.8% during 2025-2032.
Computational tools can identify early signs of coronary artery disease or myocardial infarction by analyzing tissue samples from the heart or vascular tissues. These tools help assess the extent of damage and predict potential outcomes, thus aiding in personalized treatment planning. These pathology also supports microbiology by enabling the analysis of microbial pathogens present in human tissue samples.
By automating the detection of pathogens in digital images, this technology accelerates diagnosis and treatment, especially in complex or rare infections. The adoption of this pathology technologies has grown rapidly, largely driven by the need for more efficient, accurate, and scalable diagnostic tools. As healthcare systems seek to modernize and integrate more advanced technologies, this pathology has emerged as a key area for improvement.
Brazil’s burgeoning AI sector, with over US$1 billion in spending in 2023 - a 33% year-over-year growth - represents a critical catalyst for developing these pathology solutions. Intelligent Process Automation (IPA) investment, which reached US$214 million in the same year, underscores a national commitment to advanced data processing and automated diagnostics. This ecosystem provides fertile ground for computational pathology, which relies heavily on AI and machine learning algorithms to analyze medical images and data with higher accuracy and speed. In the UAE, the government’s proactive approach to healthcare - evident in the allocation of 8.4% of the USD 15.8 billion federal budget for 2022 - demonstrates its dedication to modernizing the sector. UAE Vision 2040 further emphasizes healthcare as a strategic priority, making the country a hub for regional healthcare innovation and distribution. This emphasis on digital transformation and quality care creates significant opportunities for adopting computational pathology. In conclusion, the synergistic rise in AI investment in Brazil, strategic healthcare prioritization in the UAE, and the urgent need to tackle chronic diseases in Saudi Arabia are collectively shaping a conducive environment for market growth.
The Brazil market dominated the LAMEA Computational Pathology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $38.9 million by 2032. The Argentina market is showcasing a CAGR of 9.7% during 2025-2032. Additionally, the UAE market would register a CAGR of 7.8% during 2025-2032.
Computational tools can identify early signs of coronary artery disease or myocardial infarction by analyzing tissue samples from the heart or vascular tissues. These tools help assess the extent of damage and predict potential outcomes, thus aiding in personalized treatment planning. These pathology also supports microbiology by enabling the analysis of microbial pathogens present in human tissue samples.
By automating the detection of pathogens in digital images, this technology accelerates diagnosis and treatment, especially in complex or rare infections. The adoption of this pathology technologies has grown rapidly, largely driven by the need for more efficient, accurate, and scalable diagnostic tools. As healthcare systems seek to modernize and integrate more advanced technologies, this pathology has emerged as a key area for improvement.
Brazil’s burgeoning AI sector, with over US$1 billion in spending in 2023 - a 33% year-over-year growth - represents a critical catalyst for developing these pathology solutions. Intelligent Process Automation (IPA) investment, which reached US$214 million in the same year, underscores a national commitment to advanced data processing and automated diagnostics. This ecosystem provides fertile ground for computational pathology, which relies heavily on AI and machine learning algorithms to analyze medical images and data with higher accuracy and speed. In the UAE, the government’s proactive approach to healthcare - evident in the allocation of 8.4% of the USD 15.8 billion federal budget for 2022 - demonstrates its dedication to modernizing the sector. UAE Vision 2040 further emphasizes healthcare as a strategic priority, making the country a hub for regional healthcare innovation and distribution. This emphasis on digital transformation and quality care creates significant opportunities for adopting computational pathology. In conclusion, the synergistic rise in AI investment in Brazil, strategic healthcare prioritization in the UAE, and the urgent need to tackle chronic diseases in Saudi Arabia are collectively shaping a conducive environment for market growth.
List of Key Companies Profiled
- Koninklijke Philips N.V.
- F.Hoffmann-La Roche Ltd.
- PathAI, Inc.
- Hamamatsu Photonics K.K.
- Olympus Corporation
- Visiopharm A/S
- Mikroscan Technologies, Inc.
- MindPeak GmbH
- Indica Labs, LLC
- Nucleai, Inc. (Nucleai)
Market Report Segmentation
By Component
- Software
- Services
By Application
- Disease Diagnosis
- Drug Discovery & Development
- Academic Research
By End-use
- Hospitals and Diagnostic Labs
- Biotechnology & Pharmaceutical Companies
- Academic and Research Institutes
- Other End-use
By Technology
- Machine Learning (ML)
- Deep Learning
- Other Machine Learning (ML)
- Computer Vision
- Natural Language Processing (NLP) Models
- Other Technology
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. LAMEA Computational Pathology Market by Component
Chapter 6. LAMEA Computational Pathology Market by Application
Chapter 7. LAMEA Computational Pathology Market by End-use
Chapter 8. LAMEA Computational Pathology Market by Technology
Chapter 9. LAMEA Computational Pathology Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Koninklijke Philips N.V.
- F. Hoffmann-La Roche Ltd.
- PathAI, Inc.
- Hamamatsu Photonics K.K.
- Olympus Corporation
- Visiopharm A/S
- Mikroscan Technologies, Inc.
- MindPeak GmbH
- Indica Labs, LLC
- Nucleai, Inc. (Nucleai)
Methodology
LOADING...
